Reply to “Activity of Fosfomycin on Clinical Isolates of Campylobacter jejuni and Campylobacter coli of Enteric Origin” | Zendy

Juan AguilarCompany | Zendy; Ibai LosArcos | Zendy; Carlos Pigrau | Zendy; Benito Almirante | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Reply to “Activity of Fosfomycin on Clinical Isolates of Campylobacter jejuni and Campylobacter coli of Enteric Origin”

Author(s) -

Juan AguilarCompany,

Ibai LosArcos,

Carlos Pigrau,

Benito Almirante

Publication year - 2017

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.02448-16

Subject(s) - campylobacter jejuni , campylobacter , microbiology and biotechnology , fosfomycin , biology , campylobacter coli , enterobacteriaceae , salmonella , enteric bacteria , antibiotics , bacteria , escherichia coli , genetics , gene

We thank Antonio Sorlózano-Puerto, José María Navarro-Marí, and José GutiérrezFernández for their comment on our paper (1, 2) and greatly appreciate their data on fosfomycin susceptibility in Campylobacter species isolates. To our knowledge, this is the first report on Campylobacter species susceptibility to fosfomycin since 1995 (3). As we stated in the Discussion, data on rates of resistance to fosfomycin in Campylobacter spp. are scarce and “further studies are needed to establish MIC breakpoints and define resistance rates in different geographical areas”; therefore, any information is of great value. Given their findings, we emphasize that determining the MIC of fosfomycin is crucial previous to deciding on its use in the therapy of difficultto-treat Campylobacter species infections.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research